Author(s): 
J Harrington, TRJ Evans

Format

Abstract

The current generation of anti-cancer agents, often referred to as molecularly targeted therapies, are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. This review focuses on these therapies, particularly as many of the drugs concerned have received considerable attention in the popular media.

Keywords Angiogenesis, apoptosis, cell cycle regulation, cellular senescence, monoclonal antibodies, tyrosine kinase

Declaration of Interests TRJ Evans has received research support and/or honoraria from a number of pharmaceutical companies whose products are discussed in this review, including Roche, Novartis, Bristol-Myers Squibb, OSI Pharmaceuticals, AstraZeneca and Bayer.

PDF